I just got off the phone with Redman. He was receptive, but I could tell he didn't want to talk about AEPP. He wouldn't give me very much information, but I did obtain some. Here goes...
FDA clinical trials phase 1 is still ongoing and results so far are good. Only side effects noted so far are redness at the injection point. Remember, this is just a safety phase. This is not an efficacy phase. Phase to will start noting it's effectiveness.
With the orphan drug designation, their need to recruit 1000's of participants for the clinical trials is dropped to around 250. By obtaining this status, that will greatly reduce the amount of money and time needed to conduct the trials.
The only insight I could get about the deal with Oncolix to purchase AEPP was the deal has not gone through yet. He didn't say they still weren't trying to make the deal. He just said it wasn't complete. He said it takes a while for such deal to be completed. He did say he is NOT a director of AEPP. He said Brian Kistler is still owner. The information on otcmarkets.com is inaccurate. He said they are still exploring other options for funding.
What I gathered from my conversation is the deal could or could not go through. Obviously he could not give me that type of information, but I can still read between the lines.
I recommend for everyone to not call them. Let them do their job.
My posts are of my opinion and should not be taken as solid trading advice. I do not have a vision of the future. I follow trends and base my decisions on that alone.
